MIC for Flucytosine in Cryptococcus Isolates From Participants in the Phase 2 Clinical Trial
| MIC, µg/mL . | Control IV Amphotericin B, No. (%) . | Oral LNC– Amphotericin B, No. (%) . | Total, No. (%) . | P Value . |
|---|---|---|---|---|
| First lumbar puncture Cryptococcus isolate | ||||
| ≤2 | 2 (14.3) | 7 (21.9) | 9 (19.6) | .317 |
| 4 | 9 (64.3) | 15 (46.9) | 24 (52.2) | |
| 8 | 3 (21.4) | 6 (18.8) | 9 (19.6) | |
| 16 | 0 (0) | 4 (12.5) | 4 (8.7) | |
| Last positive lumbar puncture Cryptococcus isolate | ||||
| ≤2 | 0 (0) | 3 (10.3) | 3 (7.5) | .451 |
| 4 | 7 (63.6) | 12 (41.4) | 19 (47.5) | |
| 8 | 4 (36.4) | 14 (48.3) | 18 (45.0) | |
| MIC, µg/mL . | Control IV Amphotericin B, No. (%) . | Oral LNC– Amphotericin B, No. (%) . | Total, No. (%) . | P Value . |
|---|---|---|---|---|
| First lumbar puncture Cryptococcus isolate | ||||
| ≤2 | 2 (14.3) | 7 (21.9) | 9 (19.6) | .317 |
| 4 | 9 (64.3) | 15 (46.9) | 24 (52.2) | |
| 8 | 3 (21.4) | 6 (18.8) | 9 (19.6) | |
| 16 | 0 (0) | 4 (12.5) | 4 (8.7) | |
| Last positive lumbar puncture Cryptococcus isolate | ||||
| ≤2 | 0 (0) | 3 (10.3) | 3 (7.5) | .451 |
| 4 | 7 (63.6) | 12 (41.4) | 19 (47.5) | |
| 8 | 4 (36.4) | 14 (48.3) | 18 (45.0) | |
The top section contains MIC values for the initial diagnostic CSF culture, before 5FC exposure. The lower section contains final CSF culture with positive Cryptococcus growth during 18 weeks of follow-up. The chi-square P value treats MIC as a categorical variable and tests for a statistical difference in the distribution of MICs between the control and oral LNC–amphotericin B groups.
Abbreviations: 5FC, flucytosine; CSF, cerebrospinal fluid; IV, intravenous; LNC, lipid nanocrystal; MIC, minimum inhibitory concentration.
MIC for Flucytosine in Cryptococcus Isolates From Participants in the Phase 2 Clinical Trial
| MIC, µg/mL . | Control IV Amphotericin B, No. (%) . | Oral LNC– Amphotericin B, No. (%) . | Total, No. (%) . | P Value . |
|---|---|---|---|---|
| First lumbar puncture Cryptococcus isolate | ||||
| ≤2 | 2 (14.3) | 7 (21.9) | 9 (19.6) | .317 |
| 4 | 9 (64.3) | 15 (46.9) | 24 (52.2) | |
| 8 | 3 (21.4) | 6 (18.8) | 9 (19.6) | |
| 16 | 0 (0) | 4 (12.5) | 4 (8.7) | |
| Last positive lumbar puncture Cryptococcus isolate | ||||
| ≤2 | 0 (0) | 3 (10.3) | 3 (7.5) | .451 |
| 4 | 7 (63.6) | 12 (41.4) | 19 (47.5) | |
| 8 | 4 (36.4) | 14 (48.3) | 18 (45.0) | |
| MIC, µg/mL . | Control IV Amphotericin B, No. (%) . | Oral LNC– Amphotericin B, No. (%) . | Total, No. (%) . | P Value . |
|---|---|---|---|---|
| First lumbar puncture Cryptococcus isolate | ||||
| ≤2 | 2 (14.3) | 7 (21.9) | 9 (19.6) | .317 |
| 4 | 9 (64.3) | 15 (46.9) | 24 (52.2) | |
| 8 | 3 (21.4) | 6 (18.8) | 9 (19.6) | |
| 16 | 0 (0) | 4 (12.5) | 4 (8.7) | |
| Last positive lumbar puncture Cryptococcus isolate | ||||
| ≤2 | 0 (0) | 3 (10.3) | 3 (7.5) | .451 |
| 4 | 7 (63.6) | 12 (41.4) | 19 (47.5) | |
| 8 | 4 (36.4) | 14 (48.3) | 18 (45.0) | |
The top section contains MIC values for the initial diagnostic CSF culture, before 5FC exposure. The lower section contains final CSF culture with positive Cryptococcus growth during 18 weeks of follow-up. The chi-square P value treats MIC as a categorical variable and tests for a statistical difference in the distribution of MICs between the control and oral LNC–amphotericin B groups.
Abbreviations: 5FC, flucytosine; CSF, cerebrospinal fluid; IV, intravenous; LNC, lipid nanocrystal; MIC, minimum inhibitory concentration.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
